Skip to main content
GenMont logo

GenMont — Investor Relations & Filings

Ticker · 3164 ISIN · TW0003164000 TW Manufacturing
Open in API
Filings indexed 1,617 across all filing types
Latest filing 2023-09-04 Director's Dealing
Country TW Taiwan
Listing TW 3164

About GenMont

www.genmont.com.tw

GenMont Biotech Inc. specializes in the research, development, and manufacturing of functional probiotics and postbiotics. The company operates advanced fermentation and production platforms for concentrated fermented milk, lactic acid bacteria powders, and functional microorganism strains. Its product portfolio features patented probiotic solutions targeting diverse health areas, including immune modulation, metabolic health, dental hygiene, digestive function, weight management, and pet wellness. Key proprietary strains include L. paracasei 33 and GMNL-32. GenMont leverages its technology platforms and extensive patent portfolio to deliver scientifically-backed health supplements. Beyond its proprietary brands, the company provides original equipment manufacturing (OEM) services, supporting the global market with high-quality probiotic and postbiotic ingredients certified by international standards.

Recent filings

Filing Released Lang Actions
112年08月內部人持股異動(事後)
Director's Dealing Classification · 95% confidence The document consists of detailed tables listing shareholdings of company insiders, including directors, independent directors, general manager, and financial department heads. It shows the number of shares held, changes in holdings, and related information. The content is focused on insider share transactions and holdings disclosures. There is no indication of financial results, earnings, management discussion, or other report types. The document is not a report publication announcement or a certification. It fits the definition of Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives (insider trades). The document length is sufficient and the content matches insider shareholding disclosures.
2023-09-04 Chinese
112年08月董事會成員及持股
Director's Dealing Classification · 95% confidence The document is a detailed disclosure of shareholdings by insiders and directors of the company 景岳生物科技股份有限公司. It lists the number of shares held, pledged shares, and related percentages for various board members and executives. There is no indication of a meeting presentation, financial report, earnings release, or any other type of report. Instead, it is a notification about insider shareholdings and pledges, which aligns with the category of Director's Dealing (DIRS), as it reports personal share transactions or holdings by company directors and executives. The document length is 2375 characters, which is consistent with a detailed insider shareholding report rather than a brief announcement or a full financial report. Therefore, the most appropriate classification is DIRS with high confidence.
2023-09-04 Chinese
112年第2季大陸投資
Regulatory Filings Classification · 95% confidence The document is a tabular disclosure of investment amounts and related financial data concerning investments in mainland China by a Taiwanese listed company. It includes details such as capital amounts, investment methods, cumulative investment amounts, and investment income recognized. The document is relatively short (1302 characters) and appears to be a regulatory disclosure related to cross-border investment limits and compliance with economic ministry regulations. There is no indication that this is a full financial report, audit report, or earnings release. It is not a management or board announcement, nor a call transcript or capital update. The content fits the profile of a regulatory filing disclosing investment information as required by authorities, but it is not a full report itself. Therefore, it best fits the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory disclosures that do not fit other categories.
2023-08-11 Chinese
功能性委員會成員
Regulatory Filings Classification · 90% confidence The document is very short (236 characters) and contains a table with company code, company name, establishment date, and member list. It appears to be a basic disclosure of company information, specifically about members and their expertise. There is no indication of financial data, report publication, voting results, or any detailed report content. It does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is more of a regulatory disclosure or general company information update. Given the lack of detailed financial or governance report content, the best fit is Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other categories.
2023-08-11 Chinese
112年第2季權益變動表
Interim / Quarterly Report Classification · 95% confidence The document contains detailed financial data specifically a consolidated statement of changes in equity for the first half of the year 2023 (民國112年上半年度) and the same period last year. It includes line items such as common stock, capital surplus, legal reserve, special reserve, undistributed earnings, retained earnings, foreign currency translation adjustments, treasury stock, and total equity attributable to the parent company and non-controlling interests. The presence of actual financial figures and comprehensive accounting data for a half-year period indicates this is a substantive financial report rather than a brief announcement or certification. The document length is 3532 characters, which is relatively short but contains detailed financial tables, consistent with an Interim / Quarterly Report. There is no indication that this is an announcement of a report or a certification letter. Therefore, the document is best classified as an Interim / Quarterly Report (IR). H1 2023
2023-08-10 Chinese
112年第2季現金流量表
Interim / Quarterly Report Classification · 95% confidence The document contains a consolidated cash flow statement for the second quarter of the fiscal year 112 (which corresponds to 2023 in the Gregorian calendar). It includes detailed financial data such as cash flows from operating, investing, and financing activities, with specific amounts and accounting items. The document length is 2100 characters, which is relatively short, but it contains actual financial statements and substantive financial data for a period shorter than a full fiscal year (half-year or quarterly). Therefore, it fits the definition of an Interim / Quarterly Report (IR). It is not merely an announcement or a certification, but actual financial data is presented. Hence, the correct classification is IR with high confidence. H1 2023
2023-08-10 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.